Gadoteridol for MR imaging of lymphatic vessels in lymphoedematous patients: initial experience after intracutaneous injection.
Identifieur interne : 003560 ( PubMed/Corpus ); précédent : 003559; suivant : 003561Gadoteridol for MR imaging of lymphatic vessels in lymphoedematous patients: initial experience after intracutaneous injection.
Auteurs : C. Lohrmann ; E. Foeldi ; J-P Bartholomae ; M. LangerSource :
- The British journal of radiology [ 1748-880X ] ; 2007.
English descriptors
- KwdEn :
- Adult, Contrast Media, Feasibility Studies, Female, Foot, Gadolinium, Heterocyclic Compounds, Humans, Image Processing, Computer-Assisted, Imaging, Three-Dimensional, Injections, Intradermal, Leg, Lymphatic Vessels (pathology), Lymphedema (pathology), Magnetic Resonance Imaging, Interventional (methods), Male, Middle Aged, Organometallic Compounds.
- MESH :
- chemical : Contrast Media, Gadolinium, Heterocyclic Compounds, Organometallic Compounds.
- methods : Magnetic Resonance Imaging, Interventional.
- pathology : Lymphatic Vessels, Lymphedema.
- Adult, Feasibility Studies, Female, Foot, Humans, Image Processing, Computer-Assisted, Imaging, Three-Dimensional, Injections, Intradermal, Leg, Male, Middle Aged.
Abstract
The aim of this study was to evaluate the feasibility of gadoteridol in visualizing lymphatic vessels of lymphoedematous patients after intracutaneous injection. 20 lower extremities in 10 lymphoedematous patients were examined. Gadoteridol (9 ml) was subdivided into five portions and injected intracutaneously into the dorsal aspect of each foot. For MRI, a three-dimensional spoiled gradient echo sequence was performed. No complications were observed during or after intracutaneous injection of gadoteridol. The lymphoedema was bilateral in seven and unilateral in three of the examined patients. Contrast enhancement of gadoteridol was detected in lymphatic vessels at the level of the lower leg in 17 lower extremities (85%). Enhancing lymphatic vessels of the upper leg were observed in 11 lower extremities (55%). Furthermore, gadoteridol enhanced 10 out of 20 inguinal lymph node groups (50%). No external iliac lymph nodes were observed in any of the patients. Regions of dermal backflow, indicating proximal lymphatic obstruction, were seen in 13 lower extremities (65%). As soon as 15 min after gadoteridol injection, accompanying venous enhancement was detected in all lower extremities (100%). MRI of lymphatic vessels in lymphoedematous patients is safe and feasible after intracutaneous injection of gadoteridol if the diagnosis of lymphoedema necessitates a better definition for optimal therapeutic planning or an objective, diagnostic baseline is required. The proposed technique represents a minimally invasive imaging method of identifying anatomical and physiological derangements in lymphatic vessels.
DOI: 10.1259/bjr/95414884
PubMed: 17704317
Links to Exploration step
pubmed:17704317Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Gadoteridol for MR imaging of lymphatic vessels in lymphoedematous patients: initial experience after intracutaneous injection.</title><author><name sortKey="Lohrmann, C" sort="Lohrmann, C" uniqKey="Lohrmann C" first="C" last="Lohrmann">C. Lohrmann</name><affiliation><nlm:affiliation>Division of Diagnostic Radiology, Department of Radiology, University Hospital of Freiburg, Hugstetter Strasse 55, D-79106, Freiburg, Germany. lohrmann@mrs1.ukl.uni-freiburg.de</nlm:affiliation></affiliation></author><author><name sortKey="Foeldi, E" sort="Foeldi, E" uniqKey="Foeldi E" first="E" last="Foeldi">E. Foeldi</name></author><author><name sortKey="Bartholomae, J P" sort="Bartholomae, J P" uniqKey="Bartholomae J" first="J-P" last="Bartholomae">J-P Bartholomae</name></author><author><name sortKey="Langer, M" sort="Langer, M" uniqKey="Langer M" first="M" last="Langer">M. Langer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17704317</idno><idno type="pmid">17704317</idno><idno type="doi">10.1259/bjr/95414884</idno><idno type="wicri:Area/PubMed/Corpus">003560</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003560</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Gadoteridol for MR imaging of lymphatic vessels in lymphoedematous patients: initial experience after intracutaneous injection.</title><author><name sortKey="Lohrmann, C" sort="Lohrmann, C" uniqKey="Lohrmann C" first="C" last="Lohrmann">C. Lohrmann</name><affiliation><nlm:affiliation>Division of Diagnostic Radiology, Department of Radiology, University Hospital of Freiburg, Hugstetter Strasse 55, D-79106, Freiburg, Germany. lohrmann@mrs1.ukl.uni-freiburg.de</nlm:affiliation></affiliation></author><author><name sortKey="Foeldi, E" sort="Foeldi, E" uniqKey="Foeldi E" first="E" last="Foeldi">E. Foeldi</name></author><author><name sortKey="Bartholomae, J P" sort="Bartholomae, J P" uniqKey="Bartholomae J" first="J-P" last="Bartholomae">J-P Bartholomae</name></author><author><name sortKey="Langer, M" sort="Langer, M" uniqKey="Langer M" first="M" last="Langer">M. Langer</name></author></analytic><series><title level="j">The British journal of radiology</title><idno type="eISSN">1748-880X</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Contrast Media</term><term>Feasibility Studies</term><term>Female</term><term>Foot</term><term>Gadolinium</term><term>Heterocyclic Compounds</term><term>Humans</term><term>Image Processing, Computer-Assisted</term><term>Imaging, Three-Dimensional</term><term>Injections, Intradermal</term><term>Leg</term><term>Lymphatic Vessels (pathology)</term><term>Lymphedema (pathology)</term><term>Magnetic Resonance Imaging, Interventional (methods)</term><term>Male</term><term>Middle Aged</term><term>Organometallic Compounds</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Contrast Media</term><term>Gadolinium</term><term>Heterocyclic Compounds</term><term>Organometallic Compounds</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Magnetic Resonance Imaging, Interventional</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lymphatic Vessels</term><term>Lymphedema</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Feasibility Studies</term><term>Female</term><term>Foot</term><term>Humans</term><term>Image Processing, Computer-Assisted</term><term>Imaging, Three-Dimensional</term><term>Injections, Intradermal</term><term>Leg</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to evaluate the feasibility of gadoteridol in visualizing lymphatic vessels of lymphoedematous patients after intracutaneous injection. 20 lower extremities in 10 lymphoedematous patients were examined. Gadoteridol (9 ml) was subdivided into five portions and injected intracutaneously into the dorsal aspect of each foot. For MRI, a three-dimensional spoiled gradient echo sequence was performed. No complications were observed during or after intracutaneous injection of gadoteridol. The lymphoedema was bilateral in seven and unilateral in three of the examined patients. Contrast enhancement of gadoteridol was detected in lymphatic vessels at the level of the lower leg in 17 lower extremities (85%). Enhancing lymphatic vessels of the upper leg were observed in 11 lower extremities (55%). Furthermore, gadoteridol enhanced 10 out of 20 inguinal lymph node groups (50%). No external iliac lymph nodes were observed in any of the patients. Regions of dermal backflow, indicating proximal lymphatic obstruction, were seen in 13 lower extremities (65%). As soon as 15 min after gadoteridol injection, accompanying venous enhancement was detected in all lower extremities (100%). MRI of lymphatic vessels in lymphoedematous patients is safe and feasible after intracutaneous injection of gadoteridol if the diagnosis of lymphoedema necessitates a better definition for optimal therapeutic planning or an objective, diagnostic baseline is required. The proposed technique represents a minimally invasive imaging method of identifying anatomical and physiological derangements in lymphatic vessels.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17704317</PMID><DateCreated><Year>2007</Year><Month>08</Month><Day>20</Day></DateCreated><DateCompleted><Year>2007</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1748-880X</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>955</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The British journal of radiology</Title><ISOAbbreviation>Br J Radiol</ISOAbbreviation></Journal><ArticleTitle>Gadoteridol for MR imaging of lymphatic vessels in lymphoedematous patients: initial experience after intracutaneous injection.</ArticleTitle><Pagination><MedlinePgn>569-73</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this study was to evaluate the feasibility of gadoteridol in visualizing lymphatic vessels of lymphoedematous patients after intracutaneous injection. 20 lower extremities in 10 lymphoedematous patients were examined. Gadoteridol (9 ml) was subdivided into five portions and injected intracutaneously into the dorsal aspect of each foot. For MRI, a three-dimensional spoiled gradient echo sequence was performed. No complications were observed during or after intracutaneous injection of gadoteridol. The lymphoedema was bilateral in seven and unilateral in three of the examined patients. Contrast enhancement of gadoteridol was detected in lymphatic vessels at the level of the lower leg in 17 lower extremities (85%). Enhancing lymphatic vessels of the upper leg were observed in 11 lower extremities (55%). Furthermore, gadoteridol enhanced 10 out of 20 inguinal lymph node groups (50%). No external iliac lymph nodes were observed in any of the patients. Regions of dermal backflow, indicating proximal lymphatic obstruction, were seen in 13 lower extremities (65%). As soon as 15 min after gadoteridol injection, accompanying venous enhancement was detected in all lower extremities (100%). MRI of lymphatic vessels in lymphoedematous patients is safe and feasible after intracutaneous injection of gadoteridol if the diagnosis of lymphoedema necessitates a better definition for optimal therapeutic planning or an objective, diagnostic baseline is required. The proposed technique represents a minimally invasive imaging method of identifying anatomical and physiological derangements in lymphatic vessels.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lohrmann</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Diagnostic Radiology, Department of Radiology, University Hospital of Freiburg, Hugstetter Strasse 55, D-79106, Freiburg, Germany. lohrmann@mrs1.ukl.uni-freiburg.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foeldi</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bartholomae</LastName><ForeName>J-P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Langer</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Radiol</MedlineTA><NlmUniqueID>0373125</NlmUniqueID><ISSNLinking>0007-1285</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006571">Heterocyclic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009942">Organometallic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0199MV609F</RegistryNumber><NameOfSubstance UI="C062402">gadoteridol</NameOfSubstance></Chemical><Chemical><RegistryNumber>AU0V1LM3JT</RegistryNumber><NameOfSubstance UI="D005682">Gadolinium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="Y">Contrast Media</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005528" MajorTopicYN="N">Foot</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005682" MajorTopicYN="N">Gadolinium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006571" MajorTopicYN="Y">Heterocyclic Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="Y">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007271" MajorTopicYN="N">Injections, Intradermal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007866" MajorTopicYN="N">Leg</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042601" MajorTopicYN="N">Lymphatic Vessels</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053783" MajorTopicYN="N">Magnetic Resonance Imaging, Interventional</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009942" MajorTopicYN="Y">Organometallic Compounds</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17704317</ArticleId><ArticleId IdType="pii">80/955/569</ArticleId><ArticleId IdType="doi">10.1259/bjr/95414884</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003560 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003560 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17704317
|texte= Gadoteridol for MR imaging of lymphatic vessels in lymphoedematous patients: initial experience after intracutaneous injection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17704317" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |